Science & Research (Drugs) > Impact Story: Determining the Clinical Benefit of Treatment Beyond Progression with Immune Checkpoint Inhibitors

Science & Research (Drugs) > Impact Story: Determining the Clinical Benefit of Treatment Beyond Progression with Immune Checkpoint Inhibitors

CDER researchers are evaluating whether it is clinically beneficial to continue to treat cancer patients with checkpoint inhibitors if their tumors do not immediately shrink in response to these drugs. To learn more, please visit: CDER Impact Story.